In a research report released Friday, MLV & Co. analyst Thomas Yip reiterated a Buy rating on Peregrine Pharmaceuticals (NASDAQ:PPHM) with a $3.
(Marketwired) — 01/16/15 — Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), today announced the presentation of clinical data related to the company’s immuno-oncology development program and …
In a research report released Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price …
In a research report released Wednesday, MLV analyst George Zavoico reiterated a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $3.50 price target, following presentation …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price target, as the company presented new data from …
In a research report sent to investors on Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a …
In a research report released today, MLV analyst George Zavoico reiterated a Buy rating on Peregrine Pharmaceuticals (NASDAQ:PPHM) with a $3.50 price target, …
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price …
In a research note published August 11, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Peregrine Pharmaceuticals (PPHM) with …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Peregrine Pharmaceuticals, Inc. (PPHM) and a $5 price target.
